# Quantifying Systemic Immunosuppression to Personalize Cancer Therapy

> **NCT05621837** · — · RECRUITING · sponsor: **Fondazione IRCCS Istituto Nazionale dei Tumori, Milano** · enrollment: 1000 (estimated)

## Conditions studied

- Melanoma
- Breast Cancer
- Renal Cell Carcinoma
- Urinary Bladder Cancer
- Squamous Cell Carcinoma of Head and Neck
- Small Cell Carcinoma
- NSCLC

## Interventions

- **OTHER:** MDSC quantification

## Key facts

- **NCT ID:** NCT05621837
- **Lead sponsor:** Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2022-03-10
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2025-05-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05621837

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05621837, "Quantifying Systemic Immunosuppression to Personalize Cancer Therapy". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT05621837. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*